Table 6.

Current ongoing clinical trials for BTLA-specific monoclonal antibodies or antagonist agents.

Name of the compound	Mechanism of action	Study phase	Trial ID	Targeted population	Status
JS004	Recombinant humanized IgG4κ monoclonal antibody specific to BTLA	Phase I	ClinicalTrials.gov NCT04278859	Patients with advanced solid tumor	Unknown
		Phase I	ClinicalTrials.gov NCT04477772-in China	Patients with recurrent/refractory malignant lymphoma	Recruiting
		Phase I	ClinicalTrials.gov NCT04773951-in China	Patients with advanced solid tumors	Recruiting
TAB004 + toripalimab	Monoclonal antibody specific to BTLA as monotherapy and in combination with an anti-PD-1 monoclonal antibody	Phase I	ClinicalTrials.gov NCT04137900	Patients with advanced unresectable solid tumor + metastatic solid tumor	Recruiting

BTLA, B- and T-cell lymphocyte attenuator.